Brainsway Ltd ADR (BWAY) Stock Price, Quote & News

Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitatio...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 2 582 4030

Website: www.brainsway.com

Address:

16 Hartum St, Har Hotzvim, Jerusalem, Israel

Doozio Apr. 10 at 1:20 AM

$NBIS da huckleberries are going thru da $$$ for this 🧠leader🐑 as da under da radar 💎 $BWAY bust outta $ASND ing bases 🐒🍌🧠⏰♾️

2 · Reply

Doozio Apr. 4 at 6:04 PM

$BWAY even stonk splits won’t stop da 🧠 way back to da east side! 🐒🍌🧠⏰♾️. Powerful 👀

0 · Reply

Bazzzigar Mar. 26 at 7:00 PM

$BWAY BBNX

0 · Reply

DARKP00L Mar. 26 at 11:37 AM

$BWAY 07:37 on Mar. 26 2026 BrainsWay Completes Additional $6M Milestone-Based Convertible Loan To Neurolief #tradeideas

0 · Reply

TheTradeXchange Mar. 26 at 11:31 AM

$BWAY - BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

0 · Reply

topstockalerts Mar. 11 at 5:27 PM

$BWAY What’s your upside target here? Momentum continues to favor the bulls 🐂. This trend has legs.

0 · Reply

AStrokeOfLuck Mar. 11 at 5:26 PM

$BWAY didn't know this was a treatment option for some

0 · Reply

mikesterz7 Mar. 11 at 12:31 PM

$BWAY 🚨 Full‑year revenue +27% to $52.2M Q4 adjusted EBITDA +53% to $2.3M Remaining performance obligations +43% to ~$70M 2026 guidance targets revenue $66–68M (27%–30% growth) and adjusted EBITDA $12–14M FDA label expansion and insurer coverage supporting commercial adoption

0 · Reply

topstockalerts Mar. 11 at 12:10 PM

$BWAY Is it going higher? Comment below..

0 · Reply

DonCorleone77 Mar. 11 at 12:05 PM

$BWAY Brainsway sees FY26 revenue $66M-$68M, consensus $64.79M The Company anticipates continued profitability and positive cash flow, targeting operating income of 13% to 14% and Adjusted EBITDA of $12 to $14 million.

0 · Reply

Here's Why Momentum in Brainsway (BWAY) Should Keep going

2026-03-19T13:44:24.000Z - 23 days ago

BrainsWay (BWAY) Invests $1M in Axis Integrated Mental Health Venture

Thu, 19 Mar 2026 07:30:00 -0400 - 23 days ago

BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

2026-03-12T13:28:54.000Z - 4 weeks ago

Micron To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday

2026-03-11T19:01:54.000Z - 4 weeks ago

BrainsWay Ltd (BRSYF) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Advances

2026-03-11T18:57:07.000Z - 4 weeks ago

BrainsWay (BWAY) Soars 10% on Strong Q4 Earnings and Optimistic 2026 Outlook

2026-03-11T18:00:33.000Z - 4 weeks ago

Q4 2025 Brainsway Ltd Earnings Call Transcript

Wed, 11 Mar 2026 09:18:29 -0400 - 4 weeks ago

BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates

Wed, 11 Mar 2026 07:30:00 -0400 - 4 weeks ago

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

2026-03-11T11:11:16.000Z - 4 weeks ago

Earnings Scheduled For March 11, 2026

2026-03-10T18:01:41.000Z - 4 weeks ago

Uncovering Potential: BrainsWay's Earnings Preview

2026-03-10T13:24:16.000Z - 4 weeks ago

Earnings To Watch: BrainsWay Ltd (BWAY) Reports Q4 2025 Result

Thu, 05 Mar 2026 06:16:08 -0500 - 5 weeks ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

2026-03-04T13:29:03.000Z - 5 weeks ago

BrainsWay (BWAY) Announces Breakthrough in Depression Treatment

Wed, 04 Mar 2026 07:30:00 -0500 - 5 weeks ago

Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

2026-03-04T12:30:00.000Z - 5 weeks ago

Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Wed, 25 Feb 2026 08:00:00 -0500 - 6 weeks ago

BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

2026-02-19T19:59:07.000Z - 7 weeks ago

BrainsWay (BWAY) Invests in Canadian Mental Health Clinics

2026-02-19T12:30:00.000Z - 7 weeks ago

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

Thu, 19 Feb 2026 07:30:00 -0500 - 7 weeks ago

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

2026-02-18T14:55:32.000Z - 7 weeks ago

BrainsWay (BWAY) Gains as Cigna Unit Eases TMS Therapy Access

Wed, 18 Feb 2026 07:30:00 -0500 - 7 weeks ago

BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

2026-02-17T13:56:11.000Z - 7 weeks ago

BrainsWay (BWAY) Initiates 2-for-1 Forward Split of ADSs

Tue, 17 Feb 2026 07:30:00 -0500 - 7 weeks ago

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

Wed, 21 Jan 2026 07:30:00 -0500 - 2 months ago

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

Mon, 12 Jan 2026 07:30:00 -0500 - 3 months ago

BrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

2026-01-07T12:51:12.000Z - 3 months ago

BrainsWay (BWAY) Gains Expanded Insurance Coverage for Depression Treatment

Wed, 07 Jan 2026 07:30:00 -0500 - 3 months ago

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

2025-12-23T17:07:00.000Z - 3 months ago

BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

Mon, 22 Dec 2025 07:30:00 -0500 - 3 months ago

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

2025-12-02T21:22:22.000Z - 4 months ago

Brainsway Ltd Analyst and Investor Day Transcript

2025-12-02T15:12:00.000Z - 4 months ago

Are Options Traders Betting on a Big Move in BrainsWay Stock?

Tue, 25 Nov 2025 07:30:00 -0500 - 4 months ago

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

2025-11-17T13:26:49.000Z - 5 months ago

BrainsWay (BWAY) Kicks Off Clinical Trial for Alcohol Use Disorder Treatment

Mon, 17 Nov 2025 07:30:00 -0500 - 5 months ago

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

2025-11-13T18:34:14.000Z - 5 months ago

BrainsWay (BWAY) Receives Updated "Buy" Rating from Analysts | BWAY Stock News

2025-11-13T11:33:40.000Z - 5 months ago

BrainsWay (BWAY) Gains FDA Nod for Expanded Use of Deep TMS in Adolescents

Thu, 13 Nov 2025 06:00:00 -0500 - 5 months ago

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

2025-11-11T21:01:26.000Z - 5 months ago

BrainsWay Ltd (BWAY) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...

2025-11-11T19:06:38.000Z - 5 months ago

Q3 2025 Brainsway Ltd Earnings Call Transcript

2025-11-11T13:04:48.000Z - 5 months ago

BrainsWay (BWAY) Q3 Revenue Surpasses Expectations, Raises 2025 Guidance

Tue, 11 Nov 2025 07:30:00 -0500 - 5 months ago

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

2025-11-11T11:11:20.000Z - 5 months ago

Earnings Scheduled For November 11, 2025

2025-11-10T15:03:35.000Z - 5 months ago

Insights into BrainsWay's Upcoming Earnings

2025-11-10T12:21:10.000Z - 5 months ago

What To Expect From BrainsWay Ltd (BWAY) Q3 2025 Earnings

Nov 4, 2025, 8:00 AM EST - 5 months ago

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

Oct 28, 2025, 8:00 AM EDT - 5 months ago

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

Oct 27, 2025, 7:30 AM EDT - 5 months ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Aug 21, 2025, 7:30 AM EDT - 8 months ago

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

Aug 20, 2025, 7:30 AM EDT - 8 months ago

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Aug 13, 2025, 7:30 AM EDT - 8 months ago

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Jun 11, 2025, 7:30 AM EDT - 10 months ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Jun 10, 2025, 8:00 AM EDT - 10 months ago

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

Jun 4, 2025, 7:30 AM EDT - 11 months ago

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

May 13, 2025, 7:30 AM EDT - 11 months ago

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Mar 11, 2025, 7:30 AM EDT - 1 year ago

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dec 12, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

Nov 20, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Nov 12, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Oct 29, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

Oct 9, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

Sep 30, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Sep 16, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces Significant Expansion on U.S. East Coast

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

Aug 29, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Aug 6, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 23, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 17, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

Jun 10, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Jun 3, 2024, 7:30 AM EDT - 2 years ago

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

May 8, 2024, 7:30 AM EDT - 2 years ago

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 4, 2024, 8:00 AM EDT - 2 years ago

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Mar 18, 2024, 7:30 AM EDT - 2 years ago

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Mar 6, 2024, 7:30 AM EST - 2 years ago

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Feb 21, 2024, 8:00 AM EST - 2 years ago

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Jan 10, 2024, 7:30 AM EST - 2 years ago

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Dec 19, 2023, 7:30 AM EST - 2 years ago

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Doozio Apr. 10 at 1:20 AM

$NBIS da huckleberries are going thru da $$$ for this 🧠leader🐑 as da under da radar 💎 $BWAY bust outta $ASND ing bases 🐒🍌🧠⏰♾️

2 · Reply

Doozio Apr. 4 at 6:04 PM

$BWAY even stonk splits won’t stop da 🧠 way back to da east side! 🐒🍌🧠⏰♾️. Powerful 👀

0 · Reply

Bazzzigar Mar. 26 at 7:00 PM

$BWAY BBNX

0 · Reply

DARKP00L Mar. 26 at 11:37 AM

$BWAY 07:37 on Mar. 26 2026 BrainsWay Completes Additional $6M Milestone-Based Convertible Loan To Neurolief #tradeideas

0 · Reply

TheTradeXchange Mar. 26 at 11:31 AM

$BWAY - BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

0 · Reply

topstockalerts Mar. 11 at 5:27 PM

$BWAY What’s your upside target here? Momentum continues to favor the bulls 🐂. This trend has legs.

0 · Reply

AStrokeOfLuck Mar. 11 at 5:26 PM

$BWAY didn't know this was a treatment option for some

0 · Reply

mikesterz7 Mar. 11 at 12:31 PM

0 · Reply

topstockalerts Mar. 11 at 12:10 PM

$BWAY Is it going higher? Comment below..

0 · Reply

DonCorleone77 Mar. 11 at 12:05 PM

0 · Reply

DonCorleone77 Mar. 11 at 12:04 PM

$BWAY Brainsway reports Q4 EPS 7c, consensus 3c Reports Q4 revenue $14.5M, consensus $14.02M. "We successfully closed out 2025 with strong momentum across our business, delivering 27% full-year revenue growth while significantly expanding profitability," said Hadar Levy, Chief Executive Officer of BrainsWay. "Demand for Deep TMS continues to accelerate, supported by expanding customer adoption, additional regulatory clearances, and growing reimbursement coverage. The FDA's recent clearance expanding Deep TMS MDD treatment to adolescents aged 15 to 21, and its clearance of our accelerated Deep TMS MDD protocol, represent meaningful growth catalysts for 2026 and beyond. In addition, our investment in Neurolief has the potential to significantly expand our addressable market and create new growth opportunities."

0 · Reply

StocktwitsEarnings Mar. 11 at 11:38 AM

$BWAY Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.16 up 100.00% YoY • Reported revenue of $14.54M up 27.43% YoY • BrainsWay expects full-year 2026 revenue of $66M to $68M, representing 27% to 30% growth, with operating income targeted at 13% to 14% and Adjusted EBITDA of $12M to $14M.

0 · Reply

resistancebreakers Mar. 11 at 11:37 AM

$BWAY

0 · Reply

Thestocktraderhubzee Mar. 11 at 11:37 AM

$BWAY BrainsWay Q4 EPS $0.04, Inline, Sales $14.545M Beat $14.011M Estimate

0 · Reply

DARKP00L Mar. 11 at 11:32 AM

$BWAY 07:32 on Mar. 11 2026 BrainsWay Sees FY2026 Sales $51.000M-$52.000M vs $64.986M Est #tradeideas

0 · Reply

DARKP00L Mar. 4 at 1:08 PM

$BWAY 07:34 on Mar. 04 2026 BrainsWay New Clinical Data Shows SWIFT Deep TMS Cuts Depression Treatment To 6 Sessions #tradeideas

0 · Reply

qlox Mar. 2 at 8:38 PM

$BWAY Stock split ??????????????

1 · Reply

BillionerOfKing Feb. 26 at 3:28 PM

$BWAY Current Stock Price: $23.69 Contracts to trade: $22.5 BWAY Mar 20 2026 Call Entry: $0.90 Exit: $1.38 ROI: 53% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 21 at 12:28 AM

$BWAY RSI: 53.25, MACD: 0.6781 Vol: 1.27, MA20: 23.53, MA50: 21.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

InstitutionalAllocator Feb. 20 at 1:07 PM

$BWAY BrainsWay develops neurostimulation devices. Adoption depends on clinical outcomes and reimbursement. Growth is gradual.

1 · Reply

kshonstocks Feb. 18 at 1:17 PM

$BWAY some gd news https://finance.yahoo.com/news/brainsway-reports-cigna-evernorth-behavioral-123000606.html

0 · Reply

LangClark580 Feb. 11 at 4:47 PM

$BWAY BWAY or unknown; not a standard ticker; speculative.

0 · Reply

Market Cap	572.47M
Revenue (ttm)	52.23M
Net Income (ttm)	7.63M
EPS (ttm)	N/A
PE Ratio	52.92
Forward PE	43.14
Profit Margin	14.61%
Debt to Equity Ratio	0.00

Volume	104,700
Avg Vol	187,202
Day's Range	N/A - N/A
Shares Out	40.03M
Stochastic %K	71%
Beta	1.10
Analysts	Strong Sell
Price Target	$15.33